LENZ Therapeutics Inc. (LENZ)
23.30
0.94 (4.20%)
At close: Jan 15, 2025, 10:17 AM
Company Description
LENZ Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia.
Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia.
The company is headquartered in Del Mar, California.
LENZ Therapeutics Inc.
| Country | n/a |
| IPO Date | Mar 22, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Evert B. Schimmelpennink |
Contact Details
Address: No Address available No city data available, | |
| Website | n/a |
Stock Details
| Ticker Symbol | n/a |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US52635N1037 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Evert B. Schimmelpennink | President, Chief Executive Officer, Secretary & Director |
| Daniel R. Chevallard CPA | Chief Financial Officer |
| Breianna Bowen | Vice President of Human Resources |
| David Murphy | Vice President of Marketing |
| Domenick Porfidia | Vice President of Sales |
| James W. McCollum | Co-Founder & Director |
| Marc G. Odrich M.D. | Chief Medical Officer |
| Marvin J. Garrett | Senior Vice President of Regulatory & Quality |
| Shawn Olsson | Chief Commercial Officer |